Targeted based therapy in nodal T-cell lymphomas

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• T-cell lymphomas (TCL) are diverse neoplasms of mature T lymphocytes.
• Recent biological insights have improved TCL classification, but clinical trials lag.
• Biomarker-driven treatments like brentuximab vedotin and ALK inhibitors show efficacy in specific TCL subtypes.

Purpose of the Study:

• To review the current status and role of targeted therapies in nodal T-cell lymphomas.
• To highlight the potential and limitations of biomarker-driven treatments in TCL.
• To discuss the need for combination therapies in T-cell lymphomagenesis.

Main Methods:

• Literature review of targeted therapies in nodal T-cell lymphomas.
• Analysis of biomarker-driven treatment efficacy and limitations.
• Discussion of ongoing clinical trials for combination therapies.

Main Results:

• Brentuximab vedotin is standard for CD30+ TCL and relapsed/refractory ALCL.
• ALK inhibitors show responses in ALK+ ALCL.
• Monotherapies targeting PI3K/mTOR, JAK/STAT, and epigenetic regulators yield unsatisfactory and non-durable responses.

Conclusions:

• Targeted therapies offer specific treatment avenues in TCL, but monotherapy limitations persist.
• Combination treatments are crucial for addressing the multistep nature of T-cell lymphomagenesis.
• Further research is needed to optimize biology/biomarker-driven strategies in TCL.